Copaxone

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
EAE is a common animal model for multiple sclerosis (MS). Immunomodulatory treatments such as glatiramer acetate (GA, Copaxone… (More)
Is this relevant?
2008
2008
PURPOSE Drusen formation in age-related macular degeneration (AMD) shares some similarities with Alzheimer's disease (AD), which… (More)
Is this relevant?
Highly Cited
2003
Highly Cited
2003
Glatiramer acetate (GA; copolymer-1, Copaxone) suppresses the induction of experimental autoimmune encephalomyelitis and reduces… (More)
Is this relevant?
2003
2003
CD4(+)CD25(high) T regulatory (Tr) cells, representing high IL-2 receptor alpha chain expressing cells, have been shown to… (More)
Is this relevant?
2001
2001
Humoral and cellular immune responses were followed in multiple sclerosis patients treated with Copolymer 1 (Cop1, glatiramer… (More)
Is this relevant?
2001
2001
The purpose of this study was to evaluate psychological, biophysical, and sociodemographic variables as predictors of adherence… (More)
Is this relevant?
2001
2001
Copolymer-1 (Copaxone or COP) inhibits experimental allergic encephalomyelitis and has beneficial effects in multiple sclerosis… (More)
Is this relevant?
Highly Cited
2000
Highly Cited
2000
We examined the effect of glatiramer acetate, a random copolymer of alanine, lysine, glutamic acid, and tyrosine, on antigen… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
1998
Highly Cited
1998
The synthetic polypeptide copolymer-1 (Cop-1; Copaxone; Glatiramer Acetate) has been recently approved as an effective treatment… (More)
Is this relevant?
Highly Cited
1998
Highly Cited
1998
When 251 relapsing-remitting patients with multiple sclerosis were randomized to receive daily subcutaneous injections of… (More)
Is this relevant?